Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Start-Up Spotlight: StemCiTerra, LLC
Posted on February 17th, 2017 by Betsy Davis in Pharma R&D
StemCiTerra, LLC is a small American start-up with a mission to make cancer treatments more effective. The company’s President & CSO, Lyubov Ostrovska, Ph.D., chats about their research.
What does StemCiTerra do?
The company develops stem cell-based medical treatment that makes tumors more sensitive to other therapies.
Tell us about the company’s background and what it aims to achieve.
StemCiterra is a small life science company developing the medical treatment that can increase effectiveness and reduce toxicity of cancer therapy. The aim is to improve the outcome of cancer therapy, patient survival, and quality of life.
Why is this research so important? What impact will it have on the industry?
StemCiTerra develops the method that solves the main problem in oncology: increasing the sensitivity ratio between tumor and normal tissue. It can make other therapies, including radio- , chemo-, immuno-, and gene therapy, more effective, and it provides additional opportunities for industry development.
Why does this research matter right now?
There is a significant medical need for the methods and technologies improving cancer therapies.
What will the next steps for the company be?
StemCiTerra has a pending patent. IP protection is its highest priority now.
Are you currently looking for partners or investment?
The company is looking for business partners and investment to develop the method and to move it through the regulatory process and clinical trials as fast as possible.
To get in contact with Lyubov Ostrovska, or to follow StemCiTerra:
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Strategic Marketing Manager
- Emerging Oncology Drugs in Pharma R&D Pipeline
- Cancer Moonshot: Report Research Trends Released
- An Update from Myelo: Expanding Our Team and Evaluating Data
- How Pharma Will Be Impacted by Trump’s Healthcare Reform Plans
- The Many Shapes and Colors of Biomarkers